MoonLake Immunotherapeutics (MLTX) stock
MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$12.50−0.37 (-2.87%)
Close on Nov 13, 2026Market cap $1.06BP/E –Yield –
MoonLake Immunotherapeutics r&d expenses
Research and development expenses are spending on new products and technology.
MoonLake Immunotherapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $229.61M, up 22.6% year over year. For fiscal 2025 it was $202.86M, up 79.9% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $202.86M | +79.9% |
| FY2024 | Dec 31, 2024 | $112.77M | +254.6% |
| FY2023 | Dec 31, 2023 | $31.80M | -24.4% |
| FY2022 | Dec 31, 2022 | $42.05M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $68.87M | +13.6% |
| Q2 FY2026 | Jun 30, 2026 | $50.22M | +0.9% |
| Q1 FY2026 | Mar 31, 2026 | $54.52M | +49.5% |
| Q4 FY2025 | Dec 31, 2025 | $56.01M | +38.8% |
| Q3 FY2025 | Sep 30, 2025 | $60.64M | +69.7% |
| Q2 FY2025 | Jun 30, 2025 | $49.76M | +110.3% |
| Q1 FY2025 | Mar 31, 2025 | $36.46M | +180.2% |
| Q4 FY2024 | Dec 31, 2024 | $40.36M | +398.4% |
| Q3 FY2024 | Sep 30, 2024 | $35.74M | +371.1% |
| Q2 FY2024 | Jun 30, 2024 | $23.66M | +171.9% |
| Q1 FY2024 | Mar 31, 2024 | $13.01M | +75.5% |
| Q4 FY2023 | Dec 31, 2023 | $8.10M | -28.8% |
| Q3 FY2023 | Sep 30, 2023 | $7.59M | -15.9% |
| Q2 FY2023 | Jun 30, 2023 | $8.70M | -23.7% |
| Q1 FY2023 | Mar 31, 2023 | $7.42M | -29.1% |
| Q4 FY2022 | Dec 31, 2022 | $11.37M | +1598.1% |
| Q3 FY2022 | Sep 30, 2022 | $9.02M | -69.8% |
| Q2 FY2022 | Jun 30, 2022 | $11.40M | – |
| Q1 FY2022 | Mar 31, 2022 | $10.45M | – |
| Q3 FY2021 | Sep 30, 2021 | $669.53K | – |
| Q2 FY2021 | Jun 30, 2021 | $29.87M | – |
See a number that looks wrong?